ABL1 and acute lymphoblastic leukemia: To elucidate the molecular mechanisms underlying the enhanced therapeutic effects of combining CD19-directed 17-DMAG nanoparticles with imatinib compared to 17-DMAG plus imatinib, we isolated splenic GFP+ CD19+ cells from BCR-ABL1+ B-ALL mice after the indicated treatments (Figure 4A) and performed RNA-seq analysis.